<DOC>
	<DOCNO>NCT02244242</DOCNO>
	<brief_summary>Study evaluate symptomatic relief afford tamsulosin hydrochloride capsule patient sign symptom benign prostatic hyperplasia ( BPH ) . Additionally provide primary care physician experience use tamsulosin hydrochloride capsule 0.4 mg daily treatment BPH</brief_summary>
	<brief_title>Study Evaluate Symptomatic Relief Effects FLOMAX® Patients With Signs Symptoms Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>Male patient ( 45 year age old ) diagnose BPH score least 13 point AUA Symptom Score Index baseline Patients baseline Prostate specific antigen ( PSA ) &gt; = 4.0 ng/ml Patients provide write informed consent prior participation study accordance regulatory requirement Patients judge investigator reliable agree cooperate test examination stipulate protocol Patients previously diagnose prostate cancer Patients abnormal Digital rectal examination ( DRE ) prostate gland baseline enlargement ( i.e. , patient suspicious area nodularity gland may indicate possible prostatic carcinoma exclude ) Patients previous invasive noninvasive surgical treatment prostate gland Patients episode acute urinary retention within four week screen visit Patients history evidence urethral stricture Patients pelvic radiotherapy Patients history chronic prostatitis Patients history neurogenic bladder Patients urinary tract infection ( i.e . positive urine culture yield pathogenic bacteria &gt; = 10**5 colony form unit per ml laboratory report urinary tract infection ) symptoms/signs indicative urinary tract infection : increase white blood cell ( WBCs ) urine ( 1530 WBC/high power field [ hpf ] , dysuria , costovertebral tenderness urinary frequency accompany fever within four week baseline Patients evidence significant renal dysfunction base upon serum creatinine great two time upper limit normal level establish central laboratory use study Patients baseline clinical laboratory test result indicate follow value : Hemoglobin : &lt; 12.0 g/dl Leukocytes : &lt; 3000 mm³ Liver enzymes : Serum Glutamic Oxaloacetic Transaminase ( SGOT ) , Serum Glutamic Pyruvic Transaminase ( SGPT ) , GammaGlutamyl Transferase ( GGT ) alkaline phosphatase ) : More two time upper limit normal level establish central laboratory use study Patients postural symptom ( e.g . lightheadedness , dizziness faint occur without change Blood Pressure ( BP ) and/or Heart Rate ( HR ) within four week baseline Patients participate another drug study within four week baseline Patients clinically relevant condition might interfere patient 's ability participate study include ( limit ) follow : neurologic , gastrointestinal , cardiovascular ( include uncontrolled hypertension define sit diastolic BP &gt; = 95 mmHg without treatment ) , hepatic , renal , psychiatric , hematologic respiratory disease clinically relevant laboratory abnormality base upon investigator 's judgment Patients cancer diagnosis cancer within five year baseline Patients receive cimetidine , warfarin herbal medication specifically treatment urological problem within four week prior baseline Patients know allergy study medication Patients currently receive finasteride treat finasteride within three month prior baseline Patients document myocardial infarction ( ECG ) within past 6 month evidence myocardial infarction ECG date could determine Patients classified New York Heart Association ( NYHA ) Class III IV congestive heart failure Patients prosthetic heart valve , cardiac device history endocarditis Patient clinically significant cardiac arrhythmia diagnose ECG whether accompany symptom ( e.g. , dizziness , presyncope , syncope , unsteadiness ) Patients receive follow drug within two week prior baseline unable discontinue drug remainder study : 1 . Alphaadrenergic block agent 2 . Alphaadrenergic agonists 3 . Drugs anticholinergic activity include antihistamine 4 . Antispasmodics 5 . Parasympathomimetics cholinomimetics</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>